The SARS-CoV-2 virus initiates infection in the human body through the binding of its S protein to the host cell receptor angiotensin-converting enzyme 2 (ACE2), which induces neutralizing antibody (NAb) responses and is therefore an important target for vaccine development (3–6). Here, ACE2 is linked to infection.